lorundrostat

Lorundrostat is a proprietary, orally administered, highly selective small molecule inhibitor of aldosterone synthase (CYP11B2), developed for the treatment of uncontrolled hypertension (uHTN), resistant hypertension (rHTN), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). It works by selectively inhibiting CYP11B2, the enzyme responsible for aldosterone production, thereby reducing plasma aldosterone levels. This mechanism distinguishes it from mineralocorticoid receptor antagonists by targeting hormone synthesis rather than receptor blockade. Lorundrostat has demonstrated significant reductions in systolic blood pressure in phase 2 and phase 3 clinical trials among patients with uncontrolled or resistant hypertension despite being on multiple antihypertensive medications. The drug shows high selectivity for aldosterone synthase over cortisol synthase and is associated with an acceptable safety profile[1][4][5][6].

Other names

lorundrostatMLS 101MLS101MLS-101